| scholarly article | Q13442814 |
| P50 | author | Liliana Schaefer | Q55296508 |
| P2093 | author name string | Lisa R Tannock | |
| Patricia Wilson | |||
| Joel Thompson | |||
| Deepa Taneja | |||
| Bonnie Mitchell | |||
| Katie Brandewie | |||
| P2860 | cites work | Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta | Q24321274 |
| The response-to-retention hypothesis of early atherogenesis | Q24629974 | ||
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 | ||
| Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications | Q28253399 | ||
| Negative regulation of transforming growth factor-beta by the proteoglycan decorin | Q28292224 | ||
| Primary human glomerular endothelial cells produce proteoglycans, and puromycin affects their posttranslational modification | Q28297280 | ||
| Intraglomerular lipid deposition in routine biopsies | Q68033816 | ||
| Immunohistological localization of apolipoproteins in the glomeruli in renal disease: specifically apoB and apoE | Q68033830 | ||
| Interactions of low density lipoprotein with rat mesangial cells | Q69704263 | ||
| Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro | Q70223767 | ||
| Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases | Q70673116 | ||
| Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice | Q71006993 | ||
| Proteoglycans and glycosaminoglycans synthesized in vitro by mesangial cells from normal and diabetic rats | Q71114607 | ||
| The effect of glucose on proteoglycans produced by cultured mesangial cells | Q72106426 | ||
| Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse | Q72383093 | ||
| Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells | Q72798923 | ||
| Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy | Q72822585 | ||
| Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease | Q73395934 | ||
| Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin | Q73644222 | ||
| Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency | Q73718901 | ||
| Renal injury in apolipoprotein E-deficient mice | Q74606513 | ||
| Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice | Q77361857 | ||
| Increased decorin mRNA in diabetic mouse kidney and in mesangial and tubular cells cultured in high glucose | Q77551909 | ||
| Podocyte proteoglycan synthesis is involved in the development of nephrotic syndrome | Q28578040 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| Elevated levels of beta defensin-1 mRNA in diabetic kidneys of GK rats. | Q33193567 | ||
| Mouse models of diabetic nephropathy | Q33821186 | ||
| Rosuvastatin and cardiovascular events in patients undergoing hemodialysis | Q34016806 | ||
| Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). | Q34164324 | ||
| Mouse models of hyperlipidemia and atherosclerosis | Q34169289 | ||
| Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice | Q34559921 | ||
| Low density lipoproteins and mitogenic signal transduction processes: role in the pathogenesis of renal disease | Q34606590 | ||
| Regulation of fibrillin-1 by biglycan and decorin is important for tissue preservation in the kidney during pressure-induced injury | Q35103026 | ||
| Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice | Q35174671 | ||
| Cellular lipid metabolism and the role of lipids in progressive renal disease | Q35621071 | ||
| Decorin deficiency enhances progressive nephropathy in diabetic mice. | Q36095577 | ||
| Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy | Q36133581 | ||
| SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance | Q36227219 | ||
| Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis | Q37201521 | ||
| Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors | Q37433274 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| Transforming growth factor-beta regulates production of proteoglycans by mesangial cells | Q38147084 | ||
| Regulation of biglycan gene expression by transforming growth factor-beta requires MKK6-p38 mitogen-activated protein Kinase signaling downstream of Smad signaling | Q38358454 | ||
| Impact of genetic background on nephropathy in diabetic mice | Q39131103 | ||
| The glomerular mesangium | Q40284542 | ||
| Biglycan, a Nitric Oxide-regulated Gene, Affects Adhesion, Growth, and Survival of Mesangial Cells | Q40651650 | ||
| Interactions between lipoproteins, glomerular cells and matrix. | Q40776214 | ||
| The extracellular matrix in diabetic nephropathy | Q40779247 | ||
| Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung | Q40806556 | ||
| Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease | Q41078715 | ||
| Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-ric | Q41664275 | ||
| Hyperlipidemia and kidney disease: concepts derived from histopathology and cell biology of the glomerulus | Q41708679 | ||
| Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs | Q43852796 | ||
| Amelioration of diabetic nephropathy in SPARC-null mice | Q44378918 | ||
| Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice. | Q44690546 | ||
| Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice | Q45085833 | ||
| Ex vivo transfer of the decorin gene into rat glomerulus via a mesangial cell vector suppressed extracellular matrix accumulation in experimental glomerulonephritis | Q45185176 | ||
| Foam cells generated by a combination of hyperglycemia and hyperlipemia in rats | Q45186670 | ||
| Can murine diabetic nephropathy be separated from superimposed acute renal failure? | Q46545514 | ||
| Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development | Q46885968 | ||
| Proteoglycans can mediate renal lipoprotein retention | Q46987479 | ||
| Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. | Q50888604 | ||
| Regulation of vascular proteoglycan synthesis by metabolic factors associated with diabetes. | Q53558779 | ||
| Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. | Q53579565 | ||
| Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. | Q53846095 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1179-1187 | |
| P577 | publication date | 2011-06-30 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy | |
| P478 | volume | 179 |
| Q38206875 | Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis |
| Q39388535 | Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells |
| Q37729228 | Biglycan- and Sphingosine Kinase-1 Signaling Crosstalk Regulates the Synthesis of Macrophage Chemoattractants. |
| Q36481626 | Biglycan: a multivalent proteoglycan providing structure and signals |
| Q46621289 | Bimodal role of NADPH oxidases in the regulation of biglycan-triggered IL-1β synthesis. |
| Q34551722 | Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs |
| Q36020284 | Decreased body fat, elevated plasma transforming growth factor-β levels, and impaired BMP4-like signaling in biglycan-deficient mice. |
| Q26996008 | Diabetic nephropathy and extracellular matrix |
| Q35536459 | Early systemic microvascular damage in pigs with atherogenic diabetes mellitus coincides with renal angiopoietin dysbalance. |
| Q47693851 | Elevated circulating TGF-β is not the cause of increased atherosclerosis development in biglycan deficient mice |
| Q38695983 | KATP channels in high glucose-induced rat mesangial cell proliferation and release of MMP-2 and fibronectin |
| Q33819300 | Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology |
| Q54646301 | Liver X receptors preserve renal glomerular integrity under normoglycaemia and in diabetes in mice. |
| Q47768797 | Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF-β inhibition |
| Q39045202 | Proposed mechanisms of Terminalia catappa in hyperglycaemia and associated diabetic complications |
| Q51348247 | Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats. |
| Q38184614 | Role of Toll-like receptors in diabetic nephropathy |
| Q38120646 | Role of dyslipidemia in patients with chronic kidney disease |
| Q47229248 | Small Leucine-Rich Proteoglycans in Renal Inflammation: Two Sides of the Coin |
| Q57787207 | Small leucine rich proteoglycans in host immunity and renal diseases |
| Q34160971 | Soluble biglycan as a biomarker of inflammatory renal diseases |
Search more.